Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will
evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+],
BRCA-mutated advanced breast cancer